Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, and Excretion of Oral [14C]GS1-144 in Healthy Postmenopausal Women
NCT07537231Phase 1Active, not recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GS1-144, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Total Radioactivity recovery rate and cumulative TRA recovery rate at 240 hours, Percentage of parent drug and its metabolites in human plasma relative to TRA exposure at 240 hours and 10 more. Started Apr 2026; status: active, not recruiting.
02
Drugs
GS1-144
Beyond the preview
Go deeper on NCT07537231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537231.